Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

Eitemau Tebyg

• Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
  gan: Jabbour, Elias, et al.
  Cyhoeddwyd: (2008)
• Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
  gan: Kantarjian, Hagop, et al.
  Cyhoeddwyd: (2012)
• The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
  gan: Jabbour, Elias, et al.
  Cyhoeddwyd: (2011)
• Homoharringtonine with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia
  gan: Maiti, Abhishek, et al.
  Cyhoeddwyd: (2017)
• Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
  gan: Jabbour, Elias, et al.
  Cyhoeddwyd: (2009)